Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04695431 · ClinicalTrials.gov registry record
Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM
A clinical trial, sponsored by Blueprint Medicines Corporation.
- Completed
- Registry status
- 317
- Enrollment target
NCT04695431 is a clinical trial that has completed, run by Blueprint Medicines Corporation. The registered enrollment target is 317 participants.
The verdict
NCT04695431 has completed, sponsored by Blueprint Medicines Corporation.
- COMPLETED
- Registry status
- 317 participants
- Enrollment target
Study Summary
BLU-285-2405 is a multi-center, synthetic control, observational and retrospective study designed to compare clinical outcomes for avapritinib compared with best available therapy for patients with AdvSM.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2020-12-02 |
| Est. Completion | 2021-10-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04695431
The ClinicalTrials.gov registry entry for NCT04695431 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 317 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Blueprint Medicines Corporation, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04695431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04695431 about?
NCT04695431 is a clinical study titled "Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM". BLU-285-2405 is a multi-center, synthetic control, observational and retrospective study designed to compare clinical outcomes for avapritinib compared with best available therapy for patients with AdvSM.
What is the current status of trial NCT04695431?
This trial is currently completed. The enrollment target is 317 participants. The study started on 2020-12-02. Estimated completion is 2021-10-04.
Who is sponsoring clinical trial NCT04695431?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.